Skip to content

Effect of Diabetes Control on Outcome in Hospitalized Patients: A National Israeli Study

Clinical Outcome of Tight Glucose Control of Diabetic Patients Hospitalized In General Internal Medicine Wards A National Israeli Study

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00813475
Enrollment
200
Registered
2008-12-23
Start date
2009-01-31
Completion date
2011-07-31
Last updated
2008-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Keywords

cardio vascular outcome

Brief summary

To test whether tight glucose control is associated with better clinical outcome compared to less-tight control, among diabetic patients hospitalized in internal medicine wards.

Detailed description

Patient characteristics: Patients admitted to internal medicine departments in public hospitals of Israel who have pre-admission diagnosis of diabetes, or have a random plasma glucose \>200 mg/dl on admission Eligibility criteria 1. Age: \>18 years 2. Fasting plasma glucose \> 140 mg/dl or non-fasting plasma glucose \>200 mg/dl in two separate blood tests if non-diabetic, or in a single blood test if have pre-diagnosed diabetes 3. Able to understand the study objective and methods and willing to provide a written informed consent 4. No significant liver disease 5. Serum creatinine \<2.0 mg/dl Exclusion criteria 1. Significant cognitive impairment 2. History of hypoglycemia unawareness or clinical autonomic diabetic neuropathy 3. Known allergy to insulin analogues 4. Diabetic ketoacidosis or non-ketotic hyperosmolar coma on admission Process of patient recruitment and randomization: 1. Enrolment of eligible patients signing the informed consent. 2. Assignment of patients to different treatment arms according to randomization scheme provided by the central organizing committee. 3. The ratio of patients' assignment to the active or to the control study arm will be 1:1 for each participating ward. Protocol: Basal bolus insulin treatment will be applied to achieve tight glucose target (mean fasting blood glucose\<130 mg/dl and not above 180 mg/dl during the day) compared to patients treated to achieve less tight glucose targets (mean fasting blood glucose\<200 mg/dl and not above 220 mg/dl during the day)will influence cardiovascular and general clinical outcome. Primary outcome: All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital Secondary outcomes: Total number of in-hospital days during one year follow-up (including the index hospital admission) The rate of any major clinical events (all-cause mortality, hospital acquired infection, organ failure, need of ventilation support, need of vasoactive amine administration, need of central line insertion, hospital admission for stroke, acute coronary event, severe bacterial or fungal infection) during one year follow-up Hypoglycemic events during index hospital stay.

Interventions

DRUGBasal bolus insulin regimen (tight glucose control)

Basal bolus insulin regimen

DRUGBasal bolus insulin regimen (standard control)

basal bolus insulin regimen

Sponsors

Assaf-Harofeh Medical Center
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Age: \>18 years 2. Fasting plasma glucose \> 140 mg/dl or non-fasting plasma glucose \>200 mg/dl in two separate blood tests if non-diabetic, or in a single blood test if have pre-diagnosed diabetes 3. Able to understand the study objective and methods and willing to provide a written informed consent 4. No significant liver disease 5. Serum creatinine \<2.0 mg/dl \-

Exclusion criteria

1. Significant cognitive impairment 2. History of hypoglycemia unawareness or clinical autonomic diabetic neuropathy 3. Known allergy to insulin analogues 4. Diabetic ketoacidosis or non-ketotic hyperosmolar coma on admission \-

Design outcomes

Primary

MeasureTime frame
All-cause mortality (including in-hospital and up to 12 months post discharge) or re-admission to hospital1.5 years

Secondary

MeasureTime frame
Total # of in-hospital days during 1 year follow-up.The rate of any major clinical events during 1 year follow-up. Hypoglycemic events during index hospital stay1.5

Countries

Israel

Contacts

Primary ContactAndreas E Buchs, MD
abuchs@asaf.health.gov.il972-57-7345025

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026